RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and cancer. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. We have discovered and advanced to clinical development one drug candidate targeting CCR4, tivumecirnon, which is in development in oncology for several tumors. We are also pursuing a range of other targets that are in earlier stages of discovery.